Europe based LifeCodexx AG famous for non-invasive prenatal DNA testing has announced its partnership with LifeCell which is India’s leading mother & baby preventive health care provider, to bring PrenaTesT qNIPT testing for the first time to India.
This test will be serviced under LifeCell flagship brand BabyShield which is the division specialised in mother & baby diagnostic services.
Mayur Abhaya, CEO and MD of Lifecell said “We are excited to bring Prenatest using qNIPT technology - the world’s most advanced NIPT technology to India that would lead to substantially lower parental anxiety, as they would be able to make better informed decisions with access to reliable and affordable test results, yet with no risk to the fetus. Our laboratory for Prenatest is being set-up and the service will be available for our customers post the month of November, this year.”
Dr. Michael Lutz, CEO of LifeCodexx AG said “We are very pleased to have partnered with LifeCell since they have a long standing expertise in the field of preventive healthcare services for mother and child in the Indian market. We are certain that our qNIPT technology will find a ready market in India due to its high cost-efficiency and rapid turnaround time and also, considering that India has a birth rate of over 25 million children per year.”
The qNIPT technology detects the presence of fetal trisomy 21 (Down Syndrome) from maternal blood and it received CE marking (European Conformity) in December 2016 last year. This certification was obtained after a successful blinded clinical validation of around 1000 samples, demonstrating a 100% credibility of test results obtained from PrenaTest.
